Clinical Review

Shared Medical Appointments and Their Effects on Achieving Diabetes Mellitus Goals in a Veteran Population

Author and Disclosure Information

 

References

The ABJ SMAs lasted from 60 to 90 minutes, depending on the level of patient participation and the size of the group. The first half of the SMA was dedicated to a group discussion, which involved the SMA team, the patient, and the patient’s family (if desired). The topic of conversation was typically guided by patient curiosity and knowledge deficits in a spontaneous and free-flowing manner; for this reason, these sessions were considered to be open.

The team also engaged in more structured focused sessions, which limited the spontaneous flow of conservation and narrowed the scope to provide targeted education about various aspects of T2DM care. During focused sessions, services such as dental, optometry, podiatry, MOVE! (a VA self-management weight reduction program), and nutrition also participated. Focused sessions addressed topics such as hypoglycemia management, eating around the holidays, sick-day management of T2DM, grocery shopping, exercise, oral health, eye care, and foot care. The specialty services were encouraged to be creative and interactive during the SMA. Many of these services used supportive literature, demonstrations, diagrams, and props to enrich the educational experience. Group discussion typically lasted 30 to 40 minutes; after which patients met individually with either a CPS or NP for medication management.

Medication management focused on optimizing T2DM therapy (both oral and injectable) to improve glycemic control. Interventions outside of T2DM therapy (eg, cholesterol, hypertension, and other risk reduction modalities) were not made, due to time constraints. Once a patient demonstrated improved working knowledge of T2DM and a clinically significant reduction in their glycosylated hemoglobin A 1c (A 1c) they were discharged from SMAs at the discretion of the SMA team. There was no set minimum or maximum duration for the SMAs.

Methods

This study was a retrospective chart review conducted at the JBVAMC and was approved by the institutional review board and the research and development committee. Patient confidentiality was maintained by identifying patients by means other than name or unique identifiers. Protected health information was accessible only by the aforementioned investigators. There was no direct patient contact during this study.

Patient lists were generated from the computerized patient record system (CPRS). Patients were tracked up to 6 months after SMA discharge or until the last SMA in which they participated. The control group was matched according to location, age, glycemic control, and time. The control group never attended an ABJ SMA but may have received regular care through their primary care provider, CPS, or endocrinologist. Prospective control group patients were randomized and reviewed sequentially to obtain the matched cohort.

The study took place at ABJ, an outpatient clinic serving veterans in northwest Indiana and surrounding areas. Inclusion criteria for the SMA group were patients with T2DM, aged ≥ 45 years, with an A 1c ≥ 8.5% seen at ABJ for T2DM from May 1, 2011, to June 30, 2013. The control group included patients with T2DM, aged ≥ 45 years, with an A 1c > 9% who never attended SMAs but may have received regular care at ABJ during the study period. The SMA group’s inclusion criteria threshold for A 1c was lower in order to maximize sample size. The control group’s inclusion criteria threshold for A 1c was higher due to use of a default reminder report called “A 1c > 9%” to generate patient lists. Patients were excluded from the study if they did not meet inclusion criteria.

Pages

Recommended Reading

Keeping Diabetes at Bay
Federal Practitioner
Experiences of Veterans With Diabetes From Shared Medical Appointments
Federal Practitioner
A Physical Therapist’s Role in Clinical Video Telehealth
Federal Practitioner
A Treatment Protocol for Patients With Diabetic Peripheral Neuropathy
Federal Practitioner
A Window Into the Genetics Behind Diabetes
Federal Practitioner
Efficacy of Patient Aligned Care Team Pharmacist Services in Reaching Diabetes and Hyperlipidemia Treatment Goals
Federal Practitioner
Confronting the Diabetes Epidemic
Federal Practitioner
Diabetic Macular Edema: Is Your Patient Going Blind?
Federal Practitioner
SGLT2 Inhibitors for Type 2 Diabetes Mellitus Treatment
Federal Practitioner
Barriers to the Prevention and Treatment of Geriatric Diabetes
Federal Practitioner

Related Articles